NE
NEUP.WA
—
Warsaw Stock Exchange
Biotechnology & Life-Science Tools
Neuca SA
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
2,55 %
Op margin
2,0 %
ROE
16,6 %
Net margin
1,3 %
Debt / equity
0,69
Beta
—
52w range
—
Volume
203
Day range
$5,31–$5,48
Prev close
$5,40
Open
$5,35
Next earnings
2026-08-09
Ex-dividend
—
TR 1Y
—
About
Neuca SA operates in the Health Care Providers & Services sector, generating revenue through healthcare-related activities, though specific operational details are not disclosed in the available data.
Business. Neuca SA operates in the Health Care Providers & Services sector, generating revenue through healthcare-related activities, though specific operational details are not disclosed in the available data.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY4 analysts
3 buy1 hold0 sell
Avg 12m price target797,67
Analyst recommendations
4 analysts · consensus BuyBuy3
Hold1
Sell0
12-month price target
797,67
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
4 analysts · indicative
Ownership
—
not yet wired
Profitability→
16,6 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to NEUP.WA. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-08-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Neuca SA operates in the Health Care Providers & Services sector, generating revenue through healthcare-related activities, though specific operational details are not disclosed in the available data.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
AI synthesis
GENERATEDNeuca SA maintains a leveraged capital structure with total liabilities of 5.18 billion PLN against total equity of 1.06 billion PLN, resulting in a debt-to-equity ratio of 0.69. The company holds long-term debt of 731 million PLN and reports a current ratio of 0.89, indicating that current liabilities exceed current assets. Operating cash flow stands at 549 million PLN, while free cash flow is 86 million PLN after capital expenditures of 125 million PLN. The risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, highlighting reliance on external financing or asset liquidation to meet short-term obligations.
Profitability metrics show a return on equity of 16.6% and a return on assets of 2.81%. The company generated 13.64 billion PLN in revenue with a gross profit of 1.56 billion PLN, implying a gross margin of approximately 11.4%. Operating income was 255 million PLN, leading to a net income of 156 million PLN, which represents a net margin of roughly 1.1%. Without cohort median data for direct comparison, these returns suggest a capital-intensive business model with thin net margins, typical of healthcare providers or services with high operational costs.
Key takeaways
- Neuca SA exhibits a leveraged balance sheet with a debt-to-equity ratio of 0.69 and a current ratio below 1.0, signaling medium liquidity risk.
- The company generates 13.64 billion PLN in revenue but maintains a thin net margin of approximately 1.1%, resulting in 156 million PLN in net income.
- Return on equity is 16.6%, indicating efficient use of shareholder capital despite the high liability base.
- Analyst consensus is positive with a mean recommendation of 2.00 (Buy) and a mean price target of 797.67 PLN.
- Dilution risk is assessed as low, with no difference between basic and diluted share counts.
- Lack of segment, geographic, and historical trend data limits the depth of operational and growth analysis.
Bull / Bear case
Generated · model-assistedBULL CASE · 4
Revenue grew 8.4% CAGR from 2022 to 2026, demonstrating consistent top-line expansion despite margin pressures.
Analysts assign a mean price target of 797.67 PLN, implying 5.1% upside from the current market price.
Cash conversion ratio of 3.13 exceeds the cohort median of 1.2, indicating superior efficiency in generating cash.
Debt-to-equity ratio of 0.50 places leverage in the low band, suggesting a conservative capital structure.
BEAR CASE · 2
Net income growth stagnated at a 0.8% CAGR, failing to keep pace with the 8.4% revenue expansion.
Long-term debt increased to 731 million PLN in 2026, reflecting a rising leverage burden over the period.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-05-21
Q1 2026 · Quarter highlights
Revenue PLN 3.56B, +5,7% YoY; Operating income +22,0% YoY.
RevenuePLN 3.56B+5,7 % YoY
Operating incomePLN 96.7M+22,0 % YoY
Net incomePLN 68.3M+41,3 % YoY
Free cash flowPLN 74.6M+23,2 % YoY
EPS—
Operating cash flow-PLN 5.2M−105,0 % YoY
Financials
Income statement
RevenuePLN 3.56B
Gross profitPLN 428.0M
Operating incomePLN 96.7M
Net incomePLN 68.3M
Margins
Gross margin12.0%
Operating margin2.7%
Net margin1.9%
FCF margin2.1%
Balance sheet
Total assetsPLN 6.14B
Total liabilitiesPLN 4.98B
Total equityPLN 1.15B
Cash & equivalentsPLN 151.9M
Long-term debtPLN 914.0M
Cash flow
Operating cash flow-PLN 5.2M
CapEx-PLN 24.6M
Free cash flowPLN 74.6M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 3.56B, +5,7% YoY
- ▍Operating income +22,0% YoY
- ▍Net income +41,3% YoY
- ▍Free cash flow +23,2% YoY
- ▍Net margin 1.9%
QUARTERLYFiled 2026-03-26
Q4 2025 · Quarter highlights
Revenue PLN 3.52B, +9,3% YoY; Operating income +12,7% YoY.
RevenuePLN 3.52B+9,3 % YoY
Operating incomePLN 54.2M+12,7 % YoY
Net incomePLN 27.1M+7,0 % YoY
Free cash flowPLN 7.9M−69,8 % YoY
EPS—
Operating cash flowPLN 548.9M+768,1 % YoY
Financials
Income statement
RevenuePLN 3.52B
Gross profitPLN 392.2M
Operating incomePLN 54.2M
Net incomePLN 27.1M
Margins
Gross margin11.1%
Operating margin1.5%
Net margin0.8%
FCF margin0.2%
Balance sheet
Total assetsPLN 6.24B
Total liabilitiesPLN 5.18B
Total equityPLN 1.06B
Cash & equivalentsPLN 137.9M
Long-term debtPLN 731.0M
Cash flow
Operating cash flowPLN 548.9M
CapEx-PLN 124.9M
Free cash flowPLN 7.9M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 3.52B, +9,3% YoY
- ▍Operating income +12,7% YoY
- ▍Net income +7,0% YoY
- ▍Free cash flow −69,8% YoY
- ▍Net margin 0.8%
QUARTERLYFiled 2025-11-20
Q3 2025 · Quarter highlights
Revenue PLN 3.49B, +9,5% YoY; Operating income +0,1% YoY.
RevenuePLN 3.49B+9,5 % YoY
Operating incomePLN 78.5M+0,1 % YoY
Net incomePLN 60.2M+43,9 % YoY
Free cash flow-PLN 10.7M−118,3 % YoY
EPS—
Operating cash flowPLN 379.9M+248,5 % YoY
Financials
Income statement
RevenuePLN 3.49B
Gross profitPLN 400.6M
Operating incomePLN 78.5M
Net incomePLN 60.2M
Margins
Gross margin11.5%
Operating margin2.3%
Net margin1.7%
FCF margin-0.3%
Balance sheet
Total assetsPLN 5.98B
Total liabilitiesPLN 4.96B
Total equityPLN 1.02B
Cash & equivalentsPLN 114.3M
Long-term debtPLN 769.9M
Cash flow
Operating cash flowPLN 379.9M
CapEx-PLN 69.7M
Free cash flow-PLN 10.7M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 3.49B, +9,5% YoY
- ▍Operating income +0,1% YoY
- ▍Net income +43,9% YoY
- ▍Free cash flow −118,3% YoY
- ▍Net margin 1.7%
QUARTERLYFiled 2025-08-28
Q2 2025 · Quarter highlights
Revenue PLN 3.27B, +7,4% YoY; Operating income −30,7% YoY.
RevenuePLN 3.27B+7,4 % YoY
Operating incomePLN 43.2M−30,7 % YoY
Net incomePLN 19.8M−35,2 % YoY
Free cash flowPLN 28.1M−34,5 % YoY
EPS—
Operating cash flowPLN 290.2M+101,7 % YoY
Financials
Income statement
RevenuePLN 3.27B
Gross profitPLN 374.7M
Operating incomePLN 43.2M
Net incomePLN 19.8M
Margins
Gross margin11.5%
Operating margin1.3%
Net margin0.6%
FCF margin0.9%
Balance sheet
Total assetsPLN 5.58B
Total liabilitiesPLN 4.53B
Total equityPLN 1.05B
Cash & equivalentsPLN 132.8M
Long-term debtPLN 602.2M
Cash flow
Operating cash flowPLN 290.2M
CapEx-PLN 41.9M
Free cash flowPLN 28.1M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 3.27B, +7,4% YoY
- ▍Operating income −30,7% YoY
- ▍Net income −35,2% YoY
- ▍Free cash flow −34,5% YoY
- ▍Net margin 0.6%
QUARTERLYFiled 2025-05-22
Q1 2025 · Quarter highlights
Revenue PLN 3.37B; Operating income PLN 79.3M.
RevenuePLN 3.37B
Operating incomePLN 79.3M
Net incomePLN 48.4M
Free cash flowPLN 60.6M
EPS—
Operating cash flowPLN 102.7M
Financials
Income statement
RevenuePLN 3.37B
Gross profitPLN 390.7M
Operating incomePLN 79.3M
Net incomePLN 48.4M
Margins
Gross margin11.6%
Operating margin2.4%
Net margin1.4%
FCF margin1.8%
Balance sheet
Total assetsPLN 5.46B
Total liabilitiesPLN 4.31B
Total equityPLN 1.15B
Cash & equivalentsPLN 120.7M
Long-term debtPLN 635.6M
Cash flow
Operating cash flowPLN 102.7M
CapEx-PLN 21.3M
Free cash flowPLN 60.6M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 3.37B
- ▍Operating income PLN 79.3M
- ▍Net margin 1.4%
QUARTERLYFiled 2025-03-27
Q4 2024 · Quarter highlights
Revenue PLN 3.22B; Operating income PLN 48.1M.
RevenuePLN 3.22B
Operating incomePLN 48.1M
Net incomePLN 25.3M
Free cash flowPLN 26.1M
EPS—
Operating cash flowPLN 63.2M
Financials
Income statement
RevenuePLN 3.22B
Gross profitPLN 352.7M
Operating incomePLN 48.1M
Net incomePLN 25.3M
Margins
Gross margin11.0%
Operating margin1.5%
Net margin0.8%
FCF margin0.8%
Balance sheet
Total assetsPLN 5.51B
Total liabilitiesPLN 4.37B
Total equityPLN 1.14B
Cash & equivalentsPLN 109.8M
Long-term debtPLN 613.3M
Cash flow
Operating cash flowPLN 63.2M
CapEx-PLN 92.9M
Free cash flowPLN 26.1M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 3.22B
- ▍Operating income PLN 48.1M
- ▍Net margin 0.8%
ANNUALFiled 2026-03-26
FY 2026 · Full-year highlights
Revenue PLN 13.64B, +8,2% YoY; Operating income −7,1% YoY.
RevenuePLN 13.64B+8,2 % YoY
Operating incomePLN 255.2M−7,1 % YoY
Net incomePLN 155.6M+0,9 % YoY
Free cash flowPLN 85.8M−35,0 % YoY
EPS—
Operating cash flowPLN 548.9M+768,1 % YoY
Financials
Income statement
RevenuePLN 13.64B
Gross profitPLN 1.56B
Operating incomePLN 255.2M
Net incomePLN 155.6M
Margins
Gross margin11.4%
Operating margin1.9%
Net margin1.1%
FCF margin0.6%
Balance sheet
Total assetsPLN 6.24B
Total liabilitiesPLN 5.18B
Total equityPLN 1.06B
Cash & equivalents—
Long-term debtPLN 731.0M
Cash flow
Operating cash flowPLN 548.9M
CapEx-PLN 124.9M
Free cash flowPLN 85.8M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 13.64B, +8,2% YoY
- ▍Operating income −7,1% YoY
- ▍Net income +0,9% YoY
- ▍Free cash flow −35,0% YoY
- ▍Net margin 1.1%
ANNUALFiled 2025-03-27
FY 2025 · Full-year highlights
Revenue PLN 12.61B, +6,8% YoY; Operating income +3,6% YoY.
RevenuePLN 12.61B+6,8 % YoY
Operating incomePLN 274.7M+3,6 % YoY
Net incomePLN 154.2M+5,5 % YoY
Free cash flowPLN 132.0M+8,5 % YoY
EPS—
Operating cash flowPLN 63.2M−78,1 % YoY
Financials
Income statement
RevenuePLN 12.61B
Gross profitPLN 1.44B
Operating incomePLN 274.7M
Net incomePLN 154.2M
Margins
Gross margin11.4%
Operating margin2.2%
Net margin1.2%
FCF margin1.0%
Balance sheet
Total assetsPLN 5.51B
Total liabilitiesPLN 4.37B
Total equityPLN 1.14B
Cash & equivalents—
Long-term debtPLN 613.3M
Cash flow
Operating cash flowPLN 63.2M
CapEx-PLN 92.9M
Free cash flowPLN 132.0M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 12.61B, +6,8% YoY
- ▍Operating income +3,6% YoY
- ▍Net income +5,5% YoY
- ▍Free cash flow +8,5% YoY
- ▍Net margin 1.2%
ANNUALFiled 2024-03-28
FY 2024 · Full-year highlights
Revenue PLN 11.81B, +5,2% YoY; Operating income +8,9% YoY.
RevenuePLN 11.81B+5,2 % YoY
Operating incomePLN 265.1M+8,9 % YoY
Net incomePLN 146.3M+6,6 % YoY
Free cash flowPLN 121.7M+6,5 % YoY
EPS—
Operating cash flowPLN 288.3M−14,2 % YoY
Financials
Income statement
RevenuePLN 11.81B
Gross profitPLN 1.31B
Operating incomePLN 265.1M
Net incomePLN 146.3M
Margins
Gross margin11.1%
Operating margin2.2%
Net margin1.2%
FCF margin1.0%
Balance sheet
Total assetsPLN 5.18B
Total liabilitiesPLN 4.18B
Total equityPLN 990.4M
Cash & equivalents—
Long-term debtPLN 529.2M
Cash flow
Operating cash flowPLN 288.3M
CapEx-PLN 94.2M
Free cash flowPLN 121.7M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 11.81B, +5,2% YoY
- ▍Operating income +8,9% YoY
- ▍Net income +6,6% YoY
- ▍Free cash flow +6,5% YoY
- ▍Net margin 1.2%
ANNUALFiled 2023-03-28
FY 2023 · Full-year highlights
Revenue PLN 11.23B, +13,9% YoY; Operating income +22,8% YoY.
RevenuePLN 11.23B+13,9 % YoY
Operating incomePLN 243.4M+22,8 % YoY
Net incomePLN 137.2M−8,9 % YoY
Free cash flowPLN 114.3M−14,8 % YoY
EPS—
Operating cash flowPLN 335.9M+11,9 % YoY
Financials
Income statement
RevenuePLN 11.23B
Gross profitPLN 1.13B
Operating incomePLN 243.4M
Net incomePLN 137.2M
Margins
Gross margin10.0%
Operating margin2.2%
Net margin1.2%
FCF margin1.0%
Balance sheet
Total assetsPLN 4.76B
Total liabilitiesPLN 3.88B
Total equityPLN 882.9M
Cash & equivalents—
Long-term debtPLN 468.0M
Cash flow
Operating cash flowPLN 335.9M
CapEx-PLN 81.4M
Free cash flowPLN 114.3M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 11.23B, +13,9% YoY
- ▍Operating income +22,8% YoY
- ▍Net income −8,9% YoY
- ▍Free cash flow −14,8% YoY
- ▍Net margin 1.2%
ANNUALFiled 2022-03-31
FY 2022 · Full-year highlights
Revenue PLN 9.86B; Operating income PLN 198.2M.
RevenuePLN 9.86B
Operating incomePLN 198.2M
Net incomePLN 150.7M
Free cash flowPLN 134.1M
EPS—
Operating cash flowPLN 300.2M
Financials
Income statement
RevenuePLN 9.86B
Gross profitPLN 1.02B
Operating incomePLN 198.2M
Net incomePLN 150.7M
Margins
Gross margin10.4%
Operating margin2.0%
Net margin1.5%
FCF margin1.4%
Balance sheet
Total assetsPLN 4.12B
Total liabilitiesPLN 3.27B
Total equityPLN 842.5M
Cash & equivalents—
Long-term debtPLN 206.9M
Cash flow
Operating cash flowPLN 300.2M
CapEx-PLN 52.8M
Free cash flowPLN 134.1M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue PLN 9.86B
- ▍Operating income PLN 198.2M
- ▍Net margin 1.5%
Valuation TTM
Market price
$759,00
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$1.06B
Net cashⓘ
-$731.0M
Current ratioⓘ
0.9
Debt / equityⓘ
0.7
ROAⓘ
2.8%
ROEⓘ
16.6%
Cash conversionⓘ
313.0%
CapEx / revenueⓘ
-0.9%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Branded / Innovative Medicines—
low · llm_fanout_v2
Pharmaceutical Distribution—
low · llm_fanout_v2
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs NEUP · multiples and returns
IQ
IQV—
Iqvia Holdings Inc
$181,94
30,9B USDP/E
22,7x
— vs self
Div yield
—
— vs self
ROE
21,9 %
+23,8 vs self
CR
CRL—
Charles River Laboratories
$230,87
11,4B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-4,6 %
-2,6 vs self
ME
MEDP—
Medpace Holdings Inc
$576,00
16,7B USDP/E
34,4x
— vs self
Div yield
—
— vs self
ROE
75,4 %
+77,3 vs self
AL
ALKS—
Alkermes PLC
$49,53
8,2B USDP/E
39,8x
— vs self
Div yield
—
— vs self
ROE
8,4 %
+10,3 vs self
PI
PIII—
P3 Health Partners Inc
$10,20
73,8M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
95,3 %
+97,3 vs self
OR
ORGO—
Organogenesis Holdings Inc
$2,38
306,2M USDP/E
9,0x
— vs self
Div yield
—
— vs self
ROE
8,5 %
+10,5 vs self
NA
NAGE—
Niagen Bioscience Inc
$3,53
281,1M USDP/E
17,4x
— vs self
Div yield
—
— vs self
ROE
22,7 %
+24,7 vs self
SP
SPRY—
Ars Pharmaceuticals Inc
$5,51
547,1M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-149,9 %
-148,0 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 50 %
EPS
Consensus EPS
47,60
Predicted surprise
-0,08
Beat probability
50 %
Analysts
4
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio 0,11 · as of 2026-07-09 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 47,60 |
| Revenue | —no estimate | —no estimate | 14,2B PLN |
| Operating income | —no estimate | —no estimate | 320,5M PLN |
Full-year consensus mean (period as reported by source) · consensus in PLN. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution4 analysts
Strong buy1
Buy2
Hold1
Sell0
Strong sell0
12-month price target$797,67 · Median $711,00
Low $660,00High $1 022,00
Operating income · consensus320,5M PLN
EPS surprise
−28,5 %
reported vs consensus · miss
Revenue surprise
−4,2 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$660,00
Mean$797,67
Median$711,00
High$1 022,00
Spot$759,00
+5.1 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin2,0 %Above P75
Net Margin1,3 %Above P75
ROE16,6 %Above P75
Capex / Rev-0,9 %Above median
D/E0,69Bottom quartile
Cash Conv3,13Best in class
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 77 243 sh5 grants5 insiders
- Director · Restricted Stock Units → Common StockAcquired 8 537grant · 2026-01-20
- Director · Restricted Stock Units → Common StockAcquired 8 537grant · 2026-01-20
- Director · Restricted Stock Units → Common StockAcquired 17 073grant · 2026-01-20
- Director · Restricted Stock Units → Common StockAcquired 8 537grant · 2026-01-20
- Director, President and CEO · Employee Stock Option (Right-to- Buy) → Common StockAcquired 34 559 @ $8,27grant · 2025-08-27
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Assetsnet_income / total_assets
- Cash Conversion Ratiooperating_cash_flow / net_income
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- Neuca SA Market data — financials · 2026-07-09
- Neuca SA Market data — analyst estimates · 2026-07-09
- Neuca SA Market data — ESG · 2026-07-09
Ownership & reference
Leadership
- Kazimierz Michal HerbaChairman of the Supervisory Board
Insider activity
Net buying1 buys · 0 sellsnet $3,3M1 insiders · last 365d
- 10% owner · Common stock, $0.00001 par value per shareBought 639 110 @ $5,14$3,3M · 2025-10-21
Short positioning
15.3Kshares short-3.1% vs prior
1days to cover
27.0%short of daily vol
1.6Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
NEUP.WACanonical
Warsaw Stock Exchange · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 101.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 9.04xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.23xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 410.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 116.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 56.0%Derived (calculated)
- Shares outstanding (annual): 5.38MSEC XBRL filing
- Total assets (annual): USD 36.6MSEC XBRL filing
- Current assets (annual): USD 23.39MSEC XBRL filing
- Total liabilities (annual): USD 6.9MSEC XBRL filing
- Cash & equivalents (annual): USD 22.17MSEC XBRL filing
- Current liabilities (annual): USD 2.59MSEC XBRL filing
- Shareholders' equity (annual): USD 29.7MSEC XBRL filing
- Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): 100.5%Derived (calculated)
- EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 98.8%Derived (calculated)
- Operating income (YoY) (2025-06-30 vs 2024-06-30): 93.7%Derived (calculated)
- Net margin (FY 2025-06-30): -2.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 98.8%Derived (calculated)
- Net income (YoY) (2025-06-30 vs 2024-06-30): 97.4%Derived (calculated)
- R&D expense (YoY) (2025-06-30 vs 2024-06-30): -4.4%Derived (calculated)
- Pre-tax income (annual): USD -838KSEC XBRL filing
- Revenue (annual): USD 15.65MSEC XBRL filing
- Total operating expenses (annual): USD 16.78MSEC XBRL filing
- Net income (annual): USD -400KSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-05-21 06:39 UTCEARNINGSQuarterly results — Q1 2026 Revenue PLN 3.56B · Net PLN 68.3M
2026-03-26 06:47 UTCEARNINGSQuarterly results — Q4 2025 Revenue PLN 3.52B · Net PLN 27.1M
2026-03-26 06:47 UTCEARNINGSAnnual results — FY 2026 Revenue PLN 13.64B · Net PLN 155.6M
2026-01-20 00:00 UTCINSIDER4 insider transactions — 2026-01 4 derivative
2026-01-20INSIDERFisher Alan acquired 17.1k sh Restricted Stock Units — Director
2026-01-20INSIDERWilson David Ian acquired 8.5k sh Restricted Stock Units — Director
2026-01-20INSIDERDavies Peter Miles Winston acquired 8.5k sh Restricted Stock Units — Director
2026-01-20INSIDERRyan Jane acquired 8.5k sh Restricted Stock Units — Director
2025-11-20 06:32 UTCEARNINGSQuarterly results — Q3 2025 Revenue PLN 3.49B · Net PLN 60.2M
2025-10-21 00:00 UTCINSIDER1 insider transaction — 2025-10 · net buy $3.3M
2025-10-21INSIDERLynx1 Capital Management LP bought 639.1k sh Common stock, $0.00001 par value per share — 10% owner ~$3.28M
2025-08-28 18:45 UTCEARNINGSQuarterly results — Q2 2025 Revenue PLN 3.27B · Net PLN 19.8M
2025-08-27 00:00 UTCINSIDER1 insider transaction — 2025-08 1 derivative
2025-08-27INSIDERPapapetropoulos Spyros acquired 34.6k sh Employee Stock Option (Right-to- Buy) — Director, President and CEO
2025-05-22 09:09 UTCEARNINGSQuarterly results — Q1 2025 Revenue PLN 3.37B · Net PLN 48.4M
2025-04-16 00:00 UTCINSIDER5 insider transactions — 2025-04 5 derivative
2025-03-27 05:27 UTCEARNINGSQuarterly results — Q4 2024 Revenue PLN 3.22B · Net PLN 25.3M
2025-03-27 05:27 UTCEARNINGSAnnual results — FY 2025 Revenue PLN 12.61B · Net PLN 154.2M
2024-03-28 20:39 UTCEARNINGSAnnual results — FY 2024 Revenue PLN 11.81B · Net PLN 146.3M
2023-03-28 00:29 UTCEARNINGSAnnual results — FY 2023 Revenue PLN 11.23B · Net PLN 137.2M
2022-03-31 01:23 UTCEARNINGSAnnual results — FY 2022 Revenue PLN 9.86B · Net PLN 150.7M
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage